Development of a HTS-assay for inhibitors of a type 2C protein phosphatase (PPM
Development of a HTS-assay for inhibitors of a type 2C protein phosphatase (PPM
批准号:
7993354
负责人:
RICHARD E HONKANEN
金额:
$14.83万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2012-05-31
关键词:
AffectApoptosisBiologicalBiological AssayBiologyCellsCommunitiesComplexDetectionDevelopmentEnd Point AssayEnvironmentEnzymesFamilyGene FamilyGrowth FactorHormonesHumanLeadMalignant NeoplasmsMammalsMeasuresMedicalMetalsMethodsMolecular BankOkadaic AcidOncogenesPathologyPharmaceutical PreparationsPhosphoric Monoester HydrolasesPhosphorylationPlayProductionProtein KinaseProtein p53Protein phosphataseProteinsReactionResearchRoleSerineSignal TransductionSpecificityStimulusTP53 geneThreonineTumor Suppressor ProteinsTyrosinebasecalyculin Acell growthcell typehigh throughput screeninghuman diseaseinhibitor/antagonistinorganic phosphatemutantprotein phosphatase 2Cpublic health relevancesenescencesmall moleculetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Human cells are constantly exposed to a variety of hormones, growth factors and other agents that affect cell growth. To integrate and interpret these external stimuli, complex signaling networks have evolved, which allow different types of cells to respond appropriately to their environment. In all mammals the reversible phosphorylation of proteins regulates many intracellular signaling networks that control cell growth, differentiation, senescence and programmed cell death (apoptosis). Protein phosphorylation occurs principally on serine, threonine and tyrosine residues, and the phosphorylation reaction is catalyzed by a large family of protein kinases. To date many compounds that function as potent and highly selective inhibitors of "key" protein kinases have been identified, and these inhibitors have proven to be powerful tools to probe the biology and pathology associated with the actions of protein kinases. In contrast, much less is known about the biology of protein phosphates. Notably the biological roles and pathology associated with phosphates belonging to the PP2C subfamily are poorly understood. To a large extent, this is due to the lack of probes. Unlike dual specificity and tyrosine phosphates, where the Cys-based catalytic mechanism allows for the development of substrate trapping mutants, the metal-based catalytic mechanism of PP2C-enzymes cannot be modified to produce substrate-trapping mutants. In addition, natural compounds that potently act on PPP-family phosphates (i.e. okadaic acid and calyculin A), do not affect PP2C activity. Therefore, tools to study PP2C-family phosphates are particularly desired by the research community. Having developed methods to produce a large amount of catalytically active PP2C4 (a known oncogene) and a fluorescent assay to reliably measure PP2C4 activity, the objective of this application is to develop a high throughput ready assay that can be used to identify specific, or highly selective, inhibitors for this biologically important phosphatase. The compounds produced from this effort will serve as powerful small molecule probes that will greatly aid efforts to elucidate the roles of PP2C4 in normal biology and human disease. They may also serve as lead compounds for the development of new drugs for medical management of human cancer.
PUBLIC HEALTH RELEVANCE: Serine/threonine protein phosphatase 2C delta (PP2C4) has emerged as a regulator of p53 signaling networks and appears to act as an oncogene. Having developed methods to produce large amounts of (PP2C4) and an assay to measure (PP2C4) activity, we proposal is to identify a specific or highly selective inhibitor by developing methods that will enable a large scale screen in conjunction with the Molecular Libraries Probe Production Centers Network (MLPCN). The compounds produced from this effort will serve as powerful tool to probe the biology and pathology associated with (PP2C4).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8337404
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8668135
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8181189
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8496113
-
项目类别:
-
资助金额:$32.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
HTP screening for inhibitors of ser/the protein phosphatase 5
-
批准号:7694097
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2009
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6183372
-
项目类别:
-
资助金额:$20.6万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6389765
-
项目类别:
-
资助金额:$21.21万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6527128
-
项目类别:
-
资助金额:$21.85万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:2752396
-
项目类别:
-
资助金额:$19.36万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2843978
-
项目类别:
-
资助金额:$24.48万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7030965
-
项目类别:
-
资助金额:$25.66万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7921141
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7027545
-
项目类别:
-
资助金额:$5.1万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:6872168
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101510
-
项目类别:
-
资助金额:$10.83万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101512
-
项目类别:
-
资助金额:$9.86万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:6774616
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:6350138
-
项目类别:
-
资助金额:$23.85万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7209837
-
项目类别:
-
资助金额:$24.92万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101511
-
项目类别:
-
资助金额:$8.75万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: